Messelink, Marianne A. http://orcid.org/0000-0002-6291-3134
Berbers, Roos M.
van Montfrans, Joris M.
Ellerbroek, Pauline M.
Gladiator, André http://orcid.org/0000-0002-9025-5626
Welsing, Paco M. J.
Leavis, Helen http://orcid.org/0000-0001-8720-3684
Clinical trials referenced in this document:
Documents that mention this clinical trial
Development of a primary care screening algorithm for the early detection of patients at risk of primary antibody deficiency
https://doi.org/10.1186/s13223-023-00790-7
Funding for this research was provided by:
Takeda Pharmaceuticals
Article History
Received: 1 June 2022
Accepted: 9 April 2023
First Online: 27 May 2023
Declarations
:
: Ethical approval for this study was received from the Medical Research Ethics Committee Utrecht, protocol number 19-748. Patients with primary antibody deficiency of the University Medical Center Utrecht provided written informed consent. The need for informed consent for the group-level primary care data of the Julius General Practitioner’s Network was waived, as this only concerns meta-level data (e.g. means and medians).
: Not applicable.
: HL and JM received consulting fees for AdBoards with Takeda Pharmaceuticals. RB received personal fees from Takeda Pharmaceuticals.